Home / Peptides
Peptides A-Z
FDA status as of 2026-11-16, the doses a label or trial actually used, and what nobody knows yet.
FDA-approved
A label sets the dose, the warnings and how to mix it.
Melanocortin agonist (Vyleesi) approved for low sexual desire in premenopausal women. 1.75 mg as needed.
Elamipretide (SS-31)Mitochondria-targeted peptide (Forzinity), approved 2025 only for Barth syndrome. Label: 40 mg daily.
Orforglipron (Foundayo)Daily GLP-1 pill from Lilly (Foundayo), approved April 2026. Not a peptide and never reconstituted.
SemaglutideWeekly GLP-1 agonist (Ozempic, Wegovy). Wegovy label: 0.25 mg start, up to 2.4 mg, or 7.2 mg (HD).
TesamorelinGHRH analogue (Egrifta) approved for HIV-associated abdominal fat. Egrifta WR: 1.28 mg daily.
TirzepatideWeekly GIP and GLP-1 agonist (Mounjaro, Zepbound). Label: 2.5 mg start, +2.5 mg every 4 weeks, max 15 mg.
In clinical trials
Doses come from published trials, not a label.
Long-acting amylin analogue from Novo Nordisk, paired with semaglutide as CagriSema. Not approved yet.
RetatrutideWeekly GIP, GLP-1 and glucagon agonist from Lilly. Phase 3, not approved; up to 28% weight loss in trials.
Not FDA-approved
No approved product; most have no established human dose.
Growth hormone fragment developed as an obesity pill. Failed phase 2b; development stopped in 2007.
BPC-15715-amino-acid peptide studied mostly in animals. Not approved; no established human dose.
CJC-1295Long-acting GHRH analogue. Not approved and not compoundable; no trial of the popular ipamorelin combo.
DSIP (delta sleep-inducing peptide)Nine-amino-acid sleep peptide from the 1970s. Mixed IV studies; advisory committee voted against it in 2026.
Epitalon (epithalon)Four-amino-acid peptide modeled on a pineal extract. Small, non-randomized studies only; no established dose.
GHK-Cu (copper peptide)Copper-binding tripeptide used in skin care. Topical studies only; no human injection data.
IpamorelinGhrelin-receptor agonist. Failed a phase 2 trial; not approved and not compoundable.
KLOW and GLOW blendsSeller-defined mixes of GHK-Cu, BPC-157, TB-500 (GLOW) plus KPV (KLOW). No human data for any blend.
KPVThree-amino-acid fragment of alpha-MSH studied in animal colitis models. No human dosing data.
MOTS-c16-amino-acid mitochondrial peptide studied in animals. Not approved; no human data for MOTS-c itself.
NAD+ injectionsCoenzyme sold alongside peptides. No approved injection; one small IV pharmacokinetic study.
SelankTuftsin-analogue peptide used in Russia. Not FDA-approved and not compoundable in the US.
SemaxNasal ACTH-fragment peptide used in Russia. Not FDA-approved; no FDA-reviewed dosing.
SermorelinThe first 29 amino acids of GHRH. Former brand Geref was withdrawn in 2009; no product is marketed today.
TB-500 (thymosin beta-4)Name used for thymosin beta-4 and for a 7-amino-acid fragment of it. Not approved; no human dose data for the fragment.
Sources
- FDA: 503A bulk drug substance categories (updated May 14, 2026, PDF)
- Federal Register (public inspection) 2026-07361: peptide category changes
- Manufacturing Chemist: FDA panel backs six peptides for pharmacy compounding
- Federal Register 2026-22192: HHS draft enforcement discretion policy for 503A compounding of certain peptides (Oct 30, 2026)
- Venable LLP: HHS announces interim enforcement discretion for certain peptides (Nov 2026)
Last checked 2026-11-16. How we pick and check sources: methodology.